false 2024 Q3 --12-31 0001085277 0001085277 2024-01-01 2024-09-30 0001085277 2024-11-14 0001085277 2024-09-30 0001085277 2023-12-31 0001085277 2024-07-01 2024-09-30 0001085277 2023-07-01 2023-09-30 0001085277 2023-01-01 2023-09-30 0001085277 us-gaap:CommonStockMember 2023-12-31 0001085277 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001085277 SKVI:StockPayableMember 2023-12-31 0001085277 us-gaap:RetainedEarningsMember 2023-12-31 0001085277 us-gaap:CommonStockMember 2024-03-31 0001085277 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001085277 SKVI:StockPayableMember 2024-03-31 0001085277 us-gaap:RetainedEarningsMember 2024-03-31 0001085277 2024-03-31 0001085277 us-gaap:CommonStockMember 2024-06-30 0001085277 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001085277 SKVI:StockPayableMember 2024-06-30 0001085277 us-gaap:RetainedEarningsMember 2024-06-30 0001085277 2024-06-30 0001085277 us-gaap:CommonStockMember 2022-12-31 0001085277 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001085277 SKVI:StockPayableMember 2022-12-31 0001085277 us-gaap:RetainedEarningsMember 2022-12-31 0001085277 2022-12-31 0001085277 us-gaap:CommonStockMember 2023-03-31 0001085277 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001085277 SKVI:StockPayableMember 2023-03-31 0001085277 us-gaap:RetainedEarningsMember 2023-03-31 0001085277 2023-03-31 0001085277 us-gaap:CommonStockMember 2023-06-30 0001085277 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001085277 SKVI:StockPayableMember 2023-06-30 0001085277 us-gaap:RetainedEarningsMember 2023-06-30 0001085277 2023-06-30 0001085277 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001085277 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001085277 SKVI:StockPayableMember 2024-01-01 2024-03-31 0001085277 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001085277 2024-01-01 2024-03-31 0001085277 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001085277 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001085277 SKVI:StockPayableMember 2024-04-01 2024-06-30 0001085277 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001085277 2024-04-01 2024-06-30 0001085277 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001085277 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001085277 SKVI:StockPayableMember 2024-07-01 2024-09-30 0001085277 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001085277 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001085277 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001085277 SKVI:StockPayableMember 2023-01-01 2023-03-31 0001085277 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001085277 2023-01-01 2023-03-31 0001085277 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001085277 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001085277 SKVI:StockPayableMember 2023-04-01 2023-06-30 0001085277 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001085277 2023-04-01 2023-06-30 0001085277 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001085277 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001085277 SKVI:StockPayableMember 2023-07-01 2023-09-30 0001085277 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001085277 us-gaap:CommonStockMember 2024-09-30 0001085277 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001085277 SKVI:StockPayableMember 2024-09-30 0001085277 us-gaap:RetainedEarningsMember 2024-09-30 0001085277 us-gaap:CommonStockMember 2023-09-30 0001085277 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001085277 SKVI:StockPayableMember 2023-09-30 0001085277 us-gaap:RetainedEarningsMember 2023-09-30 0001085277 2023-09-30 0001085277 1999-12-06 2024-09-30 0001085277 SKVI:NeededForXBRLConflictOfDashAndZeroMember 2023-07-01 2023-09-30 0001085277 SKVI:ConvertibleNotePayableJan2023Member 2023-01-31 0001085277 SKVI:ConvertibleNotePayableJan2023Member 2023-01-31 2023-01-31 0001085277 SKVI:ConvertibleNotePayableJan2023Member 2024-09-30 0001085277 SKVI:ConvertibleNotePayableJan2023Member 2023-12-31 0001085277 SKVI:NineteenNotesPayableMember 2018-12-31 0001085277 SKVI:NineteenNotesPayableMember 2013-05-22 2018-12-31 0001085277 SKVI:ConvertibleNoteOneMember 2024-09-30 0001085277 SKVI:ConvertibleNoteOneMember 2023-12-31 0001085277 SKVI:ConvertibleNoteOneRenagotioatedMember 2019-09-30 0001085277 SKVI:ConvertibleNoteOneRenagotioatedMember 2019-09-30 2019-09-30 0001085277 SKVI:ConvertibleNoteOneRenagotioatedMember 2024-01-01 2024-09-30 0001085277 SKVI:ConvertibleNotePayableJune2019Member 2024-01-01 2024-09-30 0001085277 SKVI:ConvertibleNotePayableJune2019Member 2023-01-01 2023-09-30 0001085277 SKVI:ConvertibleNoteOneRenagotioatedMember 2024-09-30 0001085277 SKVI:ConvertibleNoteOneRenagotioatedMember 2023-12-31 0001085277 SKVI:ConvertibleNoteInvestorsMember 2024-09-30 0001085277 SKVI:ConvertibleNoteInvestorsMember 2024-01-01 2024-09-30 0001085277 SKVI:ConvertibleNoteInvestorsMember 2023-12-31 0001085277 SKVI:TotalConvertibleNotesMember 2024-09-30 0001085277 SKVI:TotalConvertibleNotesMember 2023-12-31 0001085277 SKVI:TotalConvertibleNotesCurrentMember 2024-09-30 0001085277 SKVI:TotalConvertibleNotesCurrentMember 2023-12-31 0001085277 SKVI:TotalLongTermConvertibleNotesCurrentMember 2024-09-30 0001085277 SKVI:TotalLongTermConvertibleNotesCurrentMember 2023-12-31 0001085277 2019-10-17 2019-10-17 0001085277 2019-10-17 2019-12-31 0001085277 SKVI:QuoinMember 2021-06-14 2021-06-14 0001085277 SKVI:DermSafeMember 2020-06-10 2020-06-10 0001085277 SKVI:May2024WarrantMember 2024-05-01 2024-05-31 0001085277 SKVI:May2024WarrantMember 2024-05-01 0001085277 SKVI:July2024WarrantMember 2024-07-09 2024-07-09 0001085277 SKVI:July2024WarrantMember 2024-07-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

☒	Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

	For the quarterly period ended September 30, 2024

☐	Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934

	For the transition period from __________ to __________

	Commission File Number: 000-25911

Skinvisible, Inc.

(Exact name of Registrant as specified in its charter)

Nevada	88-0344219
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)

6320 South Sandhill Road, Suite 10, Las Vegas, NV 89120

(Address of principal executive offices)

702.433.7154

(Registrant’s telephone number)

_______________________________________________________________

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
None		None		None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

☐ Large accelerated filer	☐ Accelerated filer
☒ Non-accelerated Filer	☒ Smaller reporting company
	☐ Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

State the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 4,889,843 common shares as of November 14, 2024.

Table of Contents

	TABLE OF CONTENTS	Page
PART I – FINANCIAL INFORMATION
Item 1:	Financial Statements	3
Item 2:	Management’s Discussion and Analysis of Financial Condition and Results of Operations	4
Item 3:	Quantitative and Qualitative Disclosures About Market Risk	10
Item 4:	Controls and Procedures	10
PART II – OTHER INFORMATION
Item 1:	Legal Proceedings	11
Item 1A:	Risk Factors	11
Item 2:	Unregistered Sales of Equity Securities and Use of Proceeds	11
Item 3:	Defaults Upon Senior Securities	11
Item 4:	Mine Safety Disclosure	11
Item 5:	Other Information	11
Item 6:	Exhibits	11

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1.

Financial Statements

Our consolidated financial statements included in this Form 10-Q are as follows:

F-1

Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 (unaudited);

F-2

Consolidated Statements of Operations for the three and nine months ended September 30, 2024 and 2023 (unaudited);

F-3

Consolidated Statements of Stockholders’ Equity (Deficit) for the three and nine months ended September 30, 2024 and 2023 (unaudited);

F-4

Consolidated Statements of Cash Flow for the nine months ended September 30, 2024 and 2023 (unaudited);

F-5

Notes to Consolidated Financial Statements.

These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and the SEC instructions to Form 10-Q. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the interim period ended September 30, 2024 are not necessarily indicative of the results that can be expected for the full year.

Table of Contents

SKINVISIBLE, INC.

CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

	September 30, 2024			December 31, 2023
ASSETS
Current assets
Cash	$	612		$	888
Accounts receivable		1,000			5,000
Due from related party		21,592			21,592
Prepaid expense and other current assets		4,200			7,980
Total current assets		27,404			35,460

Patents and trademarks, net		121,239			127,409

Total assets	$	148,643		$	162,869

LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities
Accounts payable and accrued liabilities	$	1,150,113		$	438,668
Accrued interest payable		2,641,522			2,575,595
Loans from related party		9,364			6,000
Loans payable		433,600			433,600
Convertible notes payable, net of unamortized debt discount of $38,300 and $63,785, respectively		401,761			40,000
Derivative liability		7,348			18,544
Total current liabilities		4,643,708			3,512,407


Convertible notes payable related party, net of unamortized discount of $0 and $0 respectively		5,372,403			5,372,403
Convertible notes payable		—			301,102

Total liabilities		10,016,111			9,185,912

Stockholders' deficit
Common stock; $0.001 par value; 200,000,000 shares authorized; 4,889,843 and 4,539,843 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively		4,890			4,540
Shares payable		1,000			—
Additional paid-in capital		30,387,555			30,352,905
Accumulated deficit		(40,260,913	)		(39,380,488	)
Total stockholders' deficit		(9,867,468	)		(9,023,043	)

Total liabilities and stockholders' deficit	$	148,643		$	162,869

See Accompanying Notes to Condensed Consolidated Financial Statements.

F-1

Table of Contents

SKINVISIBLE, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)


	Three months ended						Nine months ended
	September 30, 2024			September 30, 2023			September 30, 2024			September 30, 2023


Revenues	$	5,000		$	5,000		$	15,000		$	15,000

Cost of revenues		—			—			—			—

Gross profit		5,000			5,000			15,000			15,000

Operating expenses
Depreciation and amortization		5,937			4,540			15,388			14,024
Selling general and administrative		124,032			113,570			390,458			354,813
Total operating expenses		129,969			118,110			405,846			368,837

Loss from operations		(124,969	)		(113,110	)		(390,846	)		(353,837	)

Other income and (expense)
Interest expense		(167,757	)		(167,757	)		(500,775	)		(1,719,393	)
Gain/(loss) on change in derivative liability		6,122			(6,651	)		11,196			(5,419	)
Total other income (expense)		(161,635	)		(174,408	)		(489,579	)		(1,724,812	)

Net income (loss)	$	(286,604	)	$	(287,518	)	$	(880,425	)	$	(2,078,649	)

Basic income (loss) per common share	$	(0.06	)	$	(0.06	)	$	(0.19	)	$	(0.46	)

Fully diluted income (loss) per common share	$	(0.06	)	$	(0.06	)	$	(0.19	)	$	(0.46	)

Basic weighted average common shares outstanding		4,539,843			4,539,843			4,539,843			4,539,843

Fully diluted weighted average common shares outstanding		4,539,843			4,539,843			4,539,843			4,539,843

See Accompanying Notes to Condensed Consolidated Financial Statements.

F-2

Table of Contents

SKINVISIBLE, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

(UNAUDITED)


	Common Stock
	Shares		Amount		Additional Paid-in Capital		Shares Payable		Accumulated Deficit			Total Stockholders' Deficit
Balance, December 31, 2023		4,539,843	$	4,540	$	30,352,905	$	—	$	(39,380,488	)	$	(9,023,043	)
Net loss		—		—		—		—		(290,372	)		(290,372	)
Balance, March 31, 2024		4,539,843	$	4,540	$	30,352,905	$	—	$	(39,670,860	)	$	(9,313,415	)
Units issued for cash		350,000	$	350	$	34,650	$	—	$	—			35,000
Net loss		—		—		—		—		(303,449	)		(303,449	)
Balance, June 30, 2024		4,889,843	$	4,890	$	30,387,555	$	—	$	(39,974,309	)	$	(9,581,864	)
Units issued for cash		—		—	$	—		1,000		—		$	1.000
Net loss		—		—		—		—		(286,604	)		(286,604	)
Balance, September 30, 2024		4,889,843	$	4,890	$	30,387,555	$	1,000	$	(40,260,913	)	$	(9,867,468	)

Balance, December 31, 2022		4,539,843	$	4,540	$	30,352,905	$	—	$	(36,998,048	)	$	(6,640,603	)
Net loss		—		—		—		—		(1,515,056	)		(1,515,056	)
Balance, March 31, 2023		4,539,843	$	4,540	$	30,352,905	$	—	$	(38,513,104	)	$	(8,155,659	)
Net loss		—		—		—		—		(276,075	)		(276,075	)
Balance, June 30, 2023		4,539,843	$	4,540	$	30,352,905	$	—	$	(38,789,179	)	$	(8,431,734	)
Net loss		—		—		—		—		(287,518	)		(287,518	)
Balance, September 30, 2023		4,539,843	$	4,540	$	30,352,905	$	—	$	(39,076,697	)	$	(8,719,252	)

See Accompanying Notes to Condensed Consolidated Financial Statements.

F-3

Table of Contents

SKINVISIBLE, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)


	Nine months ended
	September 30, 2024			September 30, 2023

Cash flows from operating activities:
Net loss	$	(880,425	)	$	(2,078,649	)
Adjustments to reconcile net loss to net cash provided (used) by operating activities:					—
Depreciation and amortization		15,388			14,024
Amortization of debt discount		38,159			1,266,088
Gain/(loss) on change in derivative liability		(11,196	)		5,419
Changes in operating assets and liabilities:
Decrease (Increase) in prepaid assets		3,780			5,505
Increase (decrease) in accounts payable and accrued liabilities		711,445			278,577
Decrease in due from related party		—			(29,111	)
Increase in accrued interest		65,927			464,833
Net cash provided used in operating activities		(52,922	)		(73,314	)

Cash flows from investing activities:
Purchase of intangible assets		(9,218	)		(9,333	)
Net cash used in investing activities		(9,218	)		(9,333	)

Cash flows from financing activities:
Common stock issued for cash		36,000			—
Proceeds on related party loans		5,164			2,000
Repayment on related party loans		(1,800	)		—
Payments on convertible notes payable		22,500			—
Net cash provided by (used in) financing activities		61,864			2,000

Net change in cash		(276	)		(80,647	)

Cash, beginning of period		888			81,378

Cash, end of period	$	612		$	731

Supplemental disclosure of cash flow information:
Cash paid for interest	$	—		$	—
Cash paid for tax	$	—		$	—

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Non-cash investing and financing activities:
Accrued salary settled with Convertible notes payable related party		—			1,152,194

See Accompanying Notes to Condensed Consolidated Financial Statements.

F-4

Table of Contents

SKINVISIBLE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2024

1. DESCRIPTION OF BUSINESS AND HISTORY

Description of business

Skinvisible, Inc., (referred to as the “Company”) is focused on the development and manufacture and sales of innovative topical, transdermal and mucosal polymer-based delivery system technologies and formulations incorporating its patent-pending formula/process for combining hydrophilic and hydrophobic polymer emulsions. The technologies and formulations have broad industry applications within the pharmaceutical, over-the-counter, personal skincare and cosmetic arenas. Additionally, the Company’s non-dermatological formulations, offer solutions for a broad spectrum of markets women’s health, pain management, and others. The Company maintains executive and sales offices in Las Vegas, Nevada.

History

The Company was incorporated in Nevada on March 6, 1998, under the name of Microbial Solutions, Inc. The Company underwent a name change on February 26, 1999, when it changed its name to Skinvisible, Inc. The Company’s subsidiary’s name of Manloe Labs, Inc. was also changed to Skinvisible Pharmaceuticals, Inc.

Skinvisible, Inc., together with its subsidiaries, shall herein be collectively referred to as the “Company.”

2. BASIS OF PRESENTATION AND GOING CONCERN

Basis of presentation

The accompanying unaudited interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Quarterly Report on Form 10-Q and Article 10 of Regulation S-X , and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s most recent Annual Financial Statements on Form 10-K filed with the SEC on April 16, 2024. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim period presented have been reflected herein. The results of operations for the interim period are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements which would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10-K, have been omitted.

The condensed consolidated balance sheet at December 31, 2023 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by generally accepted accounting principles in the U.S. for complete financial statements.

Going concern

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. For the nine months ended September 30, 2024, the Company had a net loss of $880,425. The Company has also incurred cumulative net losses of $40,260,913 since its inception and requires capital for its contemplated operational and marketing activities to take place. These factors, among others, raises substantial doubt about the Company’s ability to continue as a going concern within one year from the date of filing.

Managements plans for the Company are to generate the necessary funding through licensing of its core products and to seek additional debt and equity funding. However, the Company’s ability to generate the necessary funds through licensing or raise additional capital through the future issuances of common stock or debt is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

F-5

Table of Contents

3. SUMMARY OF SIGNIFICANT POLICIES

This summary of significant accounting policies of Skinvisible Inc. is presented to assist in understanding the Company’s consolidated financial statements. The consolidated financial statements and notes are representations of the Company’s management, who are responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the consolidated financial statements.

Principles of consolidation

The consolidated financial statements include the accounts of the Company and its subsidiary Skinvisible Pharmaceuticals Inc. All significant intercompany balances and transactions have been eliminated.

Use of estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include estimates used to review the Company’s, impairments and estimations of long-lived assets, allowances for uncollectible accounts, inventory valuation, and the valuations of non-cash capital stock issuances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Cash and cash equivalents

For purposes of the statement of cash flows, the Company considers all highly liquid investments and short-term instruments with original maturities of three months or less to be cash equivalents.

Fair Value of financial instruments

The carrying value of cash, accounts payable and accrued expenses, and debt approximate their fair values because of the short-term nature of these instruments. Management believes the Company is not exposed to significant interest or credit risks arising from these financial instruments. The carrying amount of the Company’s convertible debt is also stated at a fair value of $5,764,477 since the stated rate of interest approximates market rates.

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable.

	•	Level 1 Quoted prices in active markets for identical assets or liabilities. These are typically obtained from real-time quotes for transactions in active exchange markets involving identical assets. The Company uses Level 1 measurements to value the transactions when it issues shares, warrants, options and debt with beneficial conversion features.

	•	Level 2 Quoted prices for similar assets and liabilities in active markets; quoted prices included for identical or similar assets and liabilities that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets. These are typically obtained from readily available pricing sources for comparable instruments. The Company did not rely on any Level 2 measurements for any of its transactions in the periods included in these financial statements.

	•	Level 3 Unobservable inputs, where there is little or no market activity for the asset or liability. These inputs reflect the reporting entity’s own beliefs about the assumptions that market participants would use in pricing the asset or liability, based on the best information available in the circumstances. The Company did not rely on any Level 3 measurements for any of its transactions in the periods included in these financial statements.

F-6

Table of Contents

Revenue recognition

We recognize revenue in accordance with generally accepted accounting principles as outlined in the Financial Accounting Standard Board's (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue From Contracts with Customers, which requires that five steps be followed in evaluating revenue recognition: (i) identify the contract with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price; and (v) recognize revenue when or as the entity satisfied a performance obligation.

Product sales – Revenues from the sale of products (Invisicare® polymers) are recognized when title to the products are transferred to the customer and only when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive reasonably assured payments for products sold and delivered.

Royalty sales – We also recognize royalty revenue from licensing our patented product formulations only when earned, with no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

Distribution and license rights sales – We also recognize revenue from distribution and license rights when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

The Company has made an accounting policy election to exclude from the measurement of the transaction price all taxes assessed by governmental authorities that are collected by the Company from its customers (sales and use taxes, value added taxes, some excise taxes).

Accounts Receivable

Accounts receivable is comprised of uncollateralized customer obligations due under normal trade terms requiring payment within 30 days from the invoice date. The carrying amount of accounts receivable is reviewed periodically for collectability. If management determines that collection is unlikely, an allowance that reflects management’s best estimate of the amounts that will not be collected is recorded. Management reviews each accounts receivable balance that exceeds 30 days from the invoice date and, based on an assessment of creditworthiness, estimates the portion, if any, of the balance that will not be collected. As of March 31, 2023 and December 31, 2022, the Company had not recorded a reserve for doubtful accounts.

Intangible assets

The Company follows Financial Accounting Standard Board’s (FASB) Codification Topic 350-10 (“ASC 350-10”), “Intangibles – Goodwill and Other”. According to this statement, intangible assets with indefinite lives are no longer subject to amortization, but rather an annual assessment of impairment by applying a fair-value based test. Under ASC 350-10, the carrying value of assets are calculated at the lowest level for which there are identifiable cash flows.

Stock-based compensation

The Company follows the guidelines in FASB Codification Topic ASC 718-10 “Compensation-Stock Compensation”, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including employee stock options and employee stock purchases related to an Employee Stock Purchase Plan based on the estimated fair values.

Earnings (loss) per share

The Company reports earnings (loss) per share in accordance with FASB Codification Topic ASC 260-10 “Earnings Per Share”, Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings (loss) per share has not been presented for the three months ending March 31, 2023, since the effect of the assumed exercise of options and warrants to purchase common shares (common stock equivalents) would have an anti-dilutive effect. There are 83,156,326 additional shares issuable in connection with outstanding convertible debts as of September 30, 2024.

F-7

Table of Contents

Recently issued accounting pronouncements

In August 2020, the FASB issued ASU 2020-06, “Debt - Debt with Conversion and Other Options (subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (subtopic 815-40),” which reduces the number of accounting models in ASC 470-20 that require separate accounting for embedded conversion features. As a result, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost as long as no other features require bifurcation and recognition as derivatives. By removing those separation models, the effective interest rate of convertible debt instruments will be closer to the coupon interest rate. Further, the diluted net income per share calculation for convertible instruments will require the Company to use the if-converted method. The treasury stock method should no longer be used to calculate diluted net income per share for convertible instruments. The amendment will be effective for the Company for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years.

4. INTANGIBLE AND OTHER ASSETS

Patents and trademarks and other intangible assets are capitalized at their historical cost and are amortized over their estimated useful lives. As of September 30, 2024, intangible assets total $121,239, net of $182,433 of accumulated amortization.

Amortization expense for the nine months ended September 30, 2024 and 2023 was $15,388 and $14,024, respectively. License and distributor rights were acquired by the Company in January 1999 and provide exclusive use distribution of polymers and polymer based products. The Company has a non-expiring term on the license and distribution rights. Accordingly, the Company annually assesses this license and distribution rights for impairment and has determined that no impairment write-down is considered necessary as of September 30, 2024.

5. RELATED PARTY TRANSACTIONS

During the nine months ended September 30, 2024 and 2023, the Company was advanced $5,614 and $2,000 and repaid $1,800 and $0 to related parties. As of September 30, 2024 and December 31, 2023, the Company had amounts due from related parties of $9,364 and $6,000, respectively.

Convertible Notes Related Party

On January 31, 2023, the Company renegotiated accrued salaries, vacation, and outstanding convertible notes for its two officers. Under the terms of the agreements, all outstanding notes totaling $4,220,209, accrued salaries of $1,062,000, accrued vacation of $90,193 were converted to promissory notes convertible into common stock with a warrant feature. The convertible promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.10 per share along with warrants to purchase one share for every two shares issued at the exercise price of $0.15 per share for three years after the conversion date. As of September 30, 2024 and December 31, 2023, the balance of the note was $5,372,402 and $5,372,402, respectively.

6. NOTES PAYABLE

Secured debt offering

During the period from May 22, 2013 and December 31, 2018, the Company entered into a 9% notes payable to nineteen investors and received proceeds of $552,000. The notes were due two years from the anniversary date of execution. The Notes are secured by the US Patent rights granted for the Company's Sunscreen Products: US patent number #8,128,913: "Sunscreen Composition with Enhanced UV-A Absorber Stability and Methods.”

As of September 30, 2024, $433,600 of the outstanding notes payable are past due and in default and have been classified as current notes payable.

F-8

Table of Contents

7. CONVERTIBLE NOTES PAYABLE

Convertible Notes Payable consists of the following:	September 30,			December 31,
	2024			2023
$40,000 face value 9% secured notes payable to investors, due in 2015. At the investor’s option until the repayment date, the note and related interest may be converted to shares of the Company’s common stock a discount of 90% of the current share price after the first anniversary of the note. The notes are secured by the accounts receivable of a license agreement the Company has with Womens Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The notes have reached maturity and are now in default, under the notes default provisions the entire balance is now due upon demand.		40,000			40,000
Original issue discount		—			—
Unamortized debt discount		—			—
Total, net of unamortized discount		40,000			40,000

On June 30, 2019, the Company renegotiated accrued salaries and interest and outstanding convertible notes for a former employee. Under the terms of the agreements, all outstanding notes totaling $224,064, accrued interest of $119,278, accrued salaries of $7,260 and accrued vacation of $1,473 were converted to a promissory note convertible into common stock with a warrant feature. The convertible promissory note is unsecured, due five years from issuance, and bears an interest rate of 10%. At the noteholder’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.20 per share along with warrants to purchase one share for every two shares issued at the exercise price of $0.30 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $152,642 as valued under the intrinsic value method. The aggregate beneficial conversion feature has been accreted and charged to interest expenses in the amount of $38,160 and $38,160 for the nine months ended September 30, 2024 and 2023, respectively.		352,075			352,075
Unamortized debt discount		(12,814	)		(50,973)
Total, net of unamortized discount		339,261			301,102

$22,500 face value 10% secured notes payable to investors, due in 2025. At the investor’s option until the repayment date, the note and related interest may be converted to shares of the Company’s common stock at the rate of $0.075. per share and 150,000 warrants exercisable at $0.10 each for 1 year from grant date.		22,500			—

Total Convertible Notes	$	401,761		$	341,102
Current portion:		401,761			40,000
Total long-term convertible notes	$	—		$	301,102

F-9

Table of Contents

8. COMMITMENTS AND CONTINGENCIES

License Agreement

On October 17, 2019, Skinvisible entered an Exclusive License Agreement with Quoin pursuant to which Skinvisible granted to Quoin a license to certain patents for the development of products for commercial sale. In exchange for the license, Quoin agreed to pay to Skinvisible a license fee of $1,000,000 and a royalty percentage on all net sales on the licensed products subject to adjustment in certain situations. The agreement also requires that Quoin make certain milestone payments to Skinvisible upon achieving regulatory approval milestones for certain drug products.

The agreement is subject to termination, if among other things, 50% of the license fee is not paid by December 31, 2019 and if the full License Fee is not paid by March 31, 2020. No payments were made by Quoin and the agreement was terminated on December 31, 2019. Both Parties subsequently determined that they continue to see the value in a partnership and therefore on May 8, 2020 and again on July 31, 2020 the companies agreed to extend the Exclusive License Agreement, as amended under the same terms to expire on September 30, 2020 and on January 27, 2021 the companies agreed to revise the milestone payments due under the agreement and to extend the agreement indefinitely.

On June 14, 2021, the Company entered into an amendment to change the terms of the license Fee as shown below.

As partial consideration for the rights conveyed by Skinvisible under this Agreement, Licensee agrees to pay to Skinvisible a one-time, non-refundable, non-creditable license issue fee of one million USD dollars ($1,000,000).

On February 3, 2020, we entered into a License Agreement with Ovation Science Inc. pursuant to which Skinvisible granted to Ovation Science Inc. a license for the manufacture and distribution rights to its hand sanitizer product, DermSafe. In exchange for the license, Ovation Science Inc. agreed to pay to Skinvisible a royalty percentage on all net sales on the licensed products subject to adjustment in certain situations plus a license fee payable in year 3 of the agreement if it chooses to continue the license. On June 10, 2020, the agreement was further amended to provide additional assignment rights for its hand sanitizer products in exchange for $100,000.

9. STOCKHOLDERS’ DEFICIT

The Company is authorized to issue 200,000,000 shares of $0.001 par value common stock. The Company had 4,889,843 and 4,539,843 issued and outstanding shares of common stock as of September 30, 2024 and December 31, 2023, respectively.

During May 2024, the Company sold 350,000 units consisting of one share of common stock and one half, one year warrant exercisable at $0.20 for $35,000.

On July 9, 2024, the Company sold 2,000 units consisting of one share of common stock and one two year warrant exercisable at $0.60 for $1,000. As of September 30, 2024, the shares have not been issued and have been included in Stock payable.

10. SUBSEQUENT EVENTS

In accordance with ASC Topic 855-10, the Company has analyzed its operations subsequent to September 30, 2024 to the date these financial statements were available to be issued and has determined that it does not have any material subsequent events to disclose in these financial statements.

F-10

Table of Contents

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations Forward-Looking Statements

This quarterly report contains forward-looking statements. Forward-looking statements are projections of events, revenues, income, future economic performance or management’s plans and objectives for our future operations. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks in the section entitled “Risk Factors” and the risks set out below, any of which may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. These risks include, by way of example and not in limitation:

•

the uncertainty of profitability based upon our history of losses;

•

legislative or regulatory changes concerning skincare research and therapies;

•

risks related to failure to obtain adequate financing on a timely basis and on acceptable terms to continue as going concern;

•

risks related to our operations and uncertainties related to our business plan and business strategy;

•

changes in economic conditions;

•

uncertainty with respect to intellectual property rights, protecting those rights and claims of infringement of other’s intellectual property;

•

competition; and

•

cybersecurity concerns.

This list is not an exhaustive list of the factors that may affect any of our forward-looking statements. These and other factors should be considered carefully, including those contained in our Annual Report on Form 10-K under “Risk Factors” for the year ended December 31, 2023, and readers should not place undue reliance on our forward-looking statements. Forward looking statements are made based on management’s beliefs, estimates and opinions on the date the statements are made, and we undertake no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Our financial statements are stated in United States dollars (US$) and are prepared in accordance with United States Generally Accepted Accounting Principles.

Company Overview

We, through our wholly owned subsidiary Skinvisible Pharmaceuticals Inc., are a pharmaceutical research and development (“R&D”) company that has developed and patented an innovative polymer delivery system, Invisicare® and formulated over forty topical skin products, which we out-license globally. We were incorporated in 1998 and target an estimated $80 billion global skincare and dermatology market and a $30 billion global over-the-counter market as well as other healthcare / medical and consumer goods markets. The Company is also exploring new opportunities in large medical markets outside of the dermatology market such as obesity and other potential markets where a topical or transdermal solution would be a viable alternative.

With the research and development complete on forty products and numerous patents issued (technology and product patents), we are ready to monetize our investment. Our business model will continue to be to out-license our patented prescription and over-the-counter (“OTC”) products featuring Invisicare to established manufacturers and marketers of brands internationally and to maximize profits from the products we have already out-licensed.

Table of Contents

The opportunity for us to license our products continues to be a viable model as the need for pharmaceutical companies to access external R&D companies for new products due to their own downsizing or elimination of internal R&D departments. The demand for our products is enhanced due to the granting of key US and international patents and the completed development of a number of unique products.

Our Flagship Product

Pivotal to our success is our patented polymer delivery system technology Invisicare. Invisicare is a patented polymer delivery system that enhances the delivery of active ingredients for topically applied skin care products. Its patented technology has a unique formula and process for combining active ingredients with a delivery system that extends the duration of time the product remains on the skin and active.

Invisicare is specifically formulated to carry water insoluble active and certain cationic active ingredients in water-based products without the use of alcohol, silicones, waxes, or other organic solvents. Products utilizing Invisicare have the proven ability to bond active ingredients to the skin for up to four hours and longer. They are non-occlusive and allow normal skin respiration and perspiration while moisturizing and protecting against exposure from a wide variety of environmental irritants.

When topically applied, these formulated products adhere to the skin's outer layers, forming a protective bond, resisting wash-off, and delivering targeted levels of therapeutic or cosmetic skincare agents to the skin. They allow enhanced delivery performance for a variety of skincare agents resulting in improved efficacy, longer duration of action, reduced irritation and lower dosage of active agent required. The "invisible" polymer compositions wear off as part of the natural exfoliation process of the skin's outer layer cells.

The advantage of products formulated with Invisicare is (1) Invisicare’s ability to bind active ingredients (the drug) to the skin, forming a protective bond on the skin, for extended periods of time; (2) Invisicare can deliver targeted levels (high or low) of therapeutic or cosmetic ingredients to the skin in a controlled release; (3) Invisicare can help to reduce the irritation of some active ingredients due to how it controls the slower release of that active ingredient; and (4) Invisicare science proves that it provides a protective skin barrier which helps retain the natural moisture content of the skin, while still allowing it to breathe. These benefits present an excellent opportunity for clear scientific advantages and marketing messages which resonate with physicians and consumers.

We generate revenue by:

LICENSING: We develop topical prescription and over-the-counter products enhanced with Invisicare to license to pharmaceutical and consumer goods companies around the world for an upfront fee and ongoing royalties.
CO-DEVELOPMENT: We assist pharmaceutical clients in the early development of the most optimal formulation, which they then take forward into clinical testing.
LIFE CYCLE MANAGEMENT: We provide cost-effective solutions to global pharmaceutical companies by reformulating their products coming off patent with a new Invisicare patent and new product benefits and line extensions. Pharmaceutical companies are under a lot of pressure to develop innovative strategies to counteract the revenue loss from their drugs coming off patent.

Table of Contents

License Agreement with Quoin

On October 17, 2019, we entered an Exclusive License Agreement with Quoin Pharmaceuticals, Inc., a Delaware corporation (“Quoin”) pursuant to which we granted Quoin a license to certain patents for the development of products for commercial sale. In exchange for the license, Quoin paid us a license fee of one million USD dollars (USD $1,000,000) (the “License Fee”) and will additionally pay a single digit royalty interest of all net sales on the licensed products subject to adjustment in certain situations. The agreement also requires that Quoin make a milestone payment of $5 million to us upon achieving the first to occur of either FDA or European Union regulatory approval for one product licensed.

In addition, and upon the successful approval in the US or European Union, whichever occurs first, Skinvisible is entitled to receive a single digit royalty percentage of Quoins net sales revenues for any licensed product covered by the patent rights licensed under the License Agreement. Plus, Quoin also agreed to pay Skinvisible 25% of any revenues they receive as royalties in the event that they sublicense any licensed products to a third party.

On June 6, 2022, the Company announced that its licensee Quoin and its product QRX003, was the first Invisicare delivery technology product to receive U.S. FDA Acceptance of Investigational New Drug Application and that Quoin was actively working towards obtaining necessary FDA and other regulatory approvals for marketing the product in the United States and other countries.

On February 14, 2024, the Company announced that there was significant progress in Quoin's clinical trials for product formulations containing Invisicare targeting Netherton Syndrome. The trials focus on the innovative formulation "QRX003," powered by Skinvisible’s Invisicare® proprietary drug delivery technology. The updates include:

	•	Positive Initial Data and Clean Safety Profile: The trials have demonstrated positive initial data and a clean safety profile, leading to the implementation of an optimization plan.

	•	Optimization Plan Implementation: Quoin has increased the size of both clinical trials significantly and adjusted dosing frequency to twice-daily from once-daily for both trials.

	•	Elimination of Lower Dose: In the blinded trial, a lower dose has been eliminated based on the positive outcomes observed.

	•	Protocol Amendments: Quoin's press release highlights protocol amendments aimed at enhancing the data set and potentially expediting regulatory approval.

We believe these protocol amendments could ultimately result in the generation of a highly compelling data set, which could support regulatory filings and approval for QRX003 as the first treatment for Netherton Syndrome.

On March 4, 2024, Quoin announced a further milestone: it received FDA Clearance to recruit teen subjects into both ongoing Netherton Syndrome clinical studies. We believe this announcement is important as:

	•	Clearance to include teen patients in both Quoin’s open label and placebo-controlled studies are expected to significantly expand the number of eligible subjects, potentially expedite recruitment and lead to a more robust data set.

	•	This development represents the first ever inclusion of non-adult subjects in Netherton Syndrome clinical studies conducted under an open Investigational New Drug Application.

	•	It is believed that the inclusion of this patient population in Quoin’s studies will be a critical component of the development of a robust data set that could result in regulatory approval with a broad label as QRX003 is being tested both as monotherapy and in conjunction with off-label treatments.

Table of Contents

On June 27, 2024, Quoin announced an International Expansion of ongoing clinical trials for Netherton Syndrome in Saudia Arabia. The site is currently treating Netherton patients who are eligible for recruitment into Quoin studies.

On October 22, 2024 Quoin announced Further International Expansion of Ongoing Clinical Trials for Netherton Syndrome with Two Additional Clinical Sites to be Opened in the United Kingdom where Both Sites are Recognized Centers of Excellence for Netherton Syndrome in the UK.

On November 5, 2024 Quoin Pharmaceuticals initiates clinical testing of lead product in pediatric Netherton Syndrome patient. This clinical assessment is being performed on a pediatric patient at children’s health Ireland in Dublin; the first evaluation of QRX003, powered by Skinvisible’s Invisicare technology, in a pediatric patient.

License Agreement with Ovation Science

On June 10, 2020, Ovation Science paid us the fee otherwise due in year 3 and in exchange we extended the term of Ovation Science’s license to 6-years and granted Ovation additional rights to its hand sanitizer products and assigned Canadian Identification Numbers 02310589 and 02355558, all DermSafe Trademarks, DermSafe clinical data and the right to patent DermSafe where not currently patented. In exchange for these rights, Ovation Science paid a $100,000 license fee. We completed the required assignments during the year ending December 31, 2020 and recognized $100,000 in revenue.

Patent Applications for Transdermal Delivery for Obesity and Glucose-Controlling Agents

In May and June of 2024, we filed provisional patent applications covering formulations that leverage Invisicare for the transdermal administration of obesity drugs and glucose-controlling agents for diseases such as diabetes. The patents are titled "Transdermal Delivery Composition for Delivery of CB-1 Receptor Antagonists and/or GLP-1 Receptor Agonists, and Method of Delivery” and “Transdermal Delivery Composition for Delivery of at Least One Glucose Controlling Agent, and Method of Delivering at Least One Glucose Controlling Agent.”

The patent applications focus on the use of Invisicare in a transdermal delivery technology designed to incorporate CB-1 receptor antagonists and/or GPL-1 receptor agonists, with drugs known for their potential in obesity management and for glucose-controlling agents, into a lotion that is applied topically to the skin using a metered applicator. Studies have demonstrated the superior transdermal penetration and controlled release of other active compounds using Invisicare's innovative technology, with certain actives exhibiting up to a tenfold increase in transdermal delivery effectiveness. By utilizing Invisicare, we aim to not only offer patients a convenient and effective alternative to traditional oral or injectable therapies but to also enhance drug efficacy and potentially significantly reduce side effects as transdermal delivery avoids first-pass metabolism. Additionally, for long-term treatment of obesity and glucose controlling agents, a transdermal delivery system could feasibly provide a convenient method for administering maintenance doses for these medications.

We are actively pursuing strategic partnerships with pharmaceutical and/or biotech companies to facilitate the introduction of the first transdermal obesity therapies to market and to explore the application of its delivery platform across diverse disease domains.

Table of Contents

Results of Operations for the Three and Nine Months Ended September 30, 2024 and 2023

Revenues

Our revenue, which we combine from product sales, royalties on patent licenses and license fees (product development fees), was $5,000 for the three months ended September 30, 2024 as compared with $5,000 for the same period ended September 30, 2023.

Our revenue, which we combine from product sales, royalties on patent licenses and license fees (product development fees), was $15,000 for the nine months ended September 30, 2024, as compared with $15,000 for the same period ended September 30, 2023.

We hope to generate more revenues from our licenses with Quoin and Ovation for the rest of 2024. We also plan to enter into commercial arrangements with pharma and biotech companies to exploit our patent applications that were recently filed, and we hope to generate revenue from these efforts in the future.

Gross Profit

We had $0 in cost of revenues for the three and nine months ended September 30, 2024, compared with $0 in cost of revenues or the three and nine months ended September 30, 2023, so our gross profit was $5,000 and $5,000 for the three and nine months ended September 30, 2024, respectively, as compared with gross profit of $15,000 and $15,000 for the three and nine ended September 30, 2023, respectively.

Our gross profit in 2024 and 2023 was due to licensing revenue, and we hope to generate more revenues from our licenses with Quoin and Ovation for the rest of 2024 and into 2025.

Operating Expenses

Operating expenses increased to $129,969 for the three months ended September 30, 2024, from $118,110 for the same period ended September 30, 2023.

Operating expenses increased to $405,846 for the nine months ended September 30, 2024, from $368,837 for the same period ended September 30, 2023.

Our operating expenses for all periods consisted mainly of selling, general and administrative expenses.

Our selling, general and administrative expenses for the nine months ended September 30, 2024, consisted mainly of accrued salaries and wages of $262,827 and audit and accounting of $37,747. In comparison, our selling, general and administrative expenses for the nine months ended September 30, 2023, consisted mainly of accrued salaries and wages of $263,329 and audit and accounting of $33,029.

We expect our operating expenses will increase in the future as the Company begins to generate more licensing revenue.

Other Expenses

We had other expenses of $161,635 for the three months ended September 30, 2024, as compared with other expenses of $174,408 for the three months ended September 30, 2023.

We had other expenses of $489,579 for the nine months ended September 30, 2024, as compared with other expenses of $1,724,812 for the nine months ended September 30, 2023.

Our other expenses for the three and nine months ended September 30, 2024 consisted mainly of interest expense, netted against a gain on settlement of debt and gain on derivative liability changes.

Table of Contents

Net Loss

We recorded a net loss of $286,604 for the three months ended September 30, 2024, as compared with a net loss of $287,518 for the three months ended September 30, 2023. We recorded a net loss of $880,425 for the nine months ended September 30, 2024, as compared with a net loss of $2,078,649 for the nine months ended September 30, 2023.

Liquidity and Capital Resources

Going concern – The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred cumulative net losses of $40,260,913 since its inception and requires capital for its contemplated operational and marketing activities to take place. The Company’s ability to generate the necessary funds through licensing of its core products or the ability to raise additional capital through the future issuances of common stock or debt is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. These factors, among others, raises substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

As of September 30, 2024, we had total current assets of $27,404 and total assets in the amount of $148,643. Our total current liabilities as of September 30, 2024 were $4,643,708. We had a working capital deficit of $4,616,304 as of September 30, 2024, compared with a working capital deficit of $3,476,947 as of December 31, 2023.

Operating activities used $52,922 in cash for the nine months ended September 30, 2024, as compared with $73,314 used for the nine months ended September 30, 2023. Our negative operating cash flows for 2023 and 2024 was largely the result of our net loss for those quarter, mainly offset by changes in operating assets and liabilities and the amortization of debt discount.

We used cash of $9,218 and $9,334 in investing activities for the nine months ended September 30, 2024 and 2023, respectively, for the purchase of intangible assets.

Cash flow provided from financing activities was $61,864 for the nine months ended September 30, 2024, as compared with $2,000 provided by cash flows for financing activities during the nine months ended September 30, 2023.

The features of the debt instruments and payables concerning our financing activities are detailed in the footnotes to our financial statements.

Based upon our current financial condition, we do not have sufficient cash to operate our business at the current level for the next twelve months. We intend to fund operations through increased sales and debt and/or equity financing arrangements, which may be insufficient to fund expenditures or other cash requirements. We plan to seek additional financing in a private equity offering to secure funding for operations. There can be no assurance that we will be successful in raising additional capital.

Off Balance Sheet Arrangements

As of September 30, 2024, there were no off-balance sheet arrangements.

Critical Accounting Policies

In December 2001, the SEC requested that all registrants list their most “critical accounting polices” in the Management Discussion and Analysis. The SEC indicated that a “critical accounting policy” is one which is both important to the portrayal of a company’s financial condition and results, and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain.

Table of Contents

Distribution and license rights sales – We also recognize revenue from distribution and license rights only when earned (and are amortized over a five-year period), with no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

Costs of Revenue – Cost of revenue includes raw materials, component parts, and shipping supplies. Shipping and handling costs is not a significant portion of the cost of revenue.

Accounts Receivable – Accounts receivable is comprised of uncollateralized customer obligations due under normal trade terms requiring payment within 30 days from the invoice date. The carrying amount of accounts receivable is reviewed periodically for collectability. If management determines that collection is unlikely, an allowance that reflects management’s best estimate of the amounts that will not be collected is recorded. Management reviews each accounts receivable balance that exceeds 30 days from the invoice date and, based on an assessment of creditworthiness, estimates the portion, if any, of the balance that will not be collected. As of September 30, 2024, we had not recorded a reserve for doubtful accounts.

Recently Issued Accounting Pronouncements

We do not expect the adoption of recently issued accounting pronouncements to have a significant impact on our results of operations, financial position or cash flow.

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

A smaller reporting company is not required to provide the information required by this Item.

Item 4.

Controls and Procedures

Disclosure Controls and Procedures

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of September 30, 2024. This evaluation was carried out under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2024, our disclosure controls and procedures were not effective due to the presence of material weaknesses in internal control over financial reporting.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis. Management has identified the following material weaknesses which have caused management to conclude that, as of September 30, 2024, our disclosure controls and procedures were not effective: (i) inadequate segregation of duties and effective risk assessment; and (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.

Remediation Plan to Address the Material Weaknesses in Internal Control over Financial Reporting

Our company plans to take steps to enhance and improve the design of our internal controls over financial reporting. During the period covered by this quarterly report on Form 10-Q, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we plan to implement the following changes during our fiscal year ending December 31, 2025: (i) appoint additional qualified personnel to address inadequate segregation of duties and ineffective risk management; and (ii) adopt sufficient written policies and procedures for accounting and financial reporting. The remediation efforts set out are largely dependent upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the three months ended September 30, 2024 that have materially affected, or are reasonable likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II – OTHER INFORMATION

Item 1.

Legal Proceedings

We are not a party to any pending legal proceeding. We are not aware of any pending legal proceeding to which any of our officers, directors, or any beneficial holders of 5% or more of our voting securities are adverse to us or have a material interest adverse to us.

Item 1A.

Risk Factors

In addition to the other information set forth in this Quarterly Report on Form 10-Q, carefully consider the risk factors described under the heading “Part I – Item 1A. Risk Factors” in our most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and “Part II – Item 1A. Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024. Such risks described are not the only risks facing us. Additional risks and uncertainties not currently known to us, or that our management currently deems to be immaterial, also may adversely affect our business, financial condition, and/or operating results. There have been no material changes to those risk factors since their disclosure in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

These securities were issued pursuant to Section 4(2) of the Securities Act and/or Rule 506 and/or Regulation S promulgated thereunder. The investor represented the intention to acquire the securities for investment only and not with a view towards distribution. The investor was given adequate information about us to make an informed investment decision. We did not engage in any general solicitation or advertising. We directed our transfer agent to issue the stock certificates with the appropriate restrictive legend affixed to the restricted stock.

Item 3.

Defaults upon Senior Securities

None

Item 4.

Mine Safety Disclosures

Not applicable.

Item 5.

Other Information

None

Item 6.

Exhibits

Exhibit Number Description of Exhibit

31.1

Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2

Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1

Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101**

The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 formatted in Extensible Business Reporting Language (XBRL).

**Provided herewith

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Skinvisible, Inc.

Date: November 19, 2024

By: /s/ Terry Howlett

Terry Howlett

Title: Chief Executive Officer, Chief Financial Officer and Director

SKINVISIBLE, INC. 10-Q